| New Threads Only: | ![]() | |||
|---|---|---|---|---|
| New Threads & Replies: | ![]() |
|
Forum List » Guru News and Commentaries Guru News, Stock picks and commentaries
Masimo Corp. CEO Joe Kiani Buys 50,000 Shares
Posted by: GuruFocus
(IP Logged)
Date: June 4, 2012 06:25PM
Masimo develops innovative monitoring technologies that significantly improve patient care — helping solve "unsolvable" problems. Masimo Corp. has a market cap of $1.08 billion; its shares were traded at around $18.4 with a P/E ratio of 18.1 and P/S ratio of 2.5. Masimo Corp. had an annual average earnings growth of 6.7% over the past 5 years.
Masimo CEO Joe Kiani has been continually increasing his positions in Masimo Corp. since the fourth quarter of 2011. His most recent purchase consisted of 50,000 shares of the compared bought at an average stock price of $18.47, costing $923,500 in total. On Nov. 22, 2011, he purchased 35,404 shares of the company, and on Oct. 28, 2011, he purchased 64,596 shares. Joe Kiani is the founder and CEO and Masimo Corp. He founded the company in 1989, and was later joined by partner Mohammed Diab. Prior to his career at Masimo, he graduated from San Diego State University at the age of 22 with Bachelor’s and Master’s degrees in electrical engineering. He is currently also active in efforts to reform U.S. health care and encourage medical innovation. John Burbank bought 100,000 shares in the quarter that ended on 03/31/2012, which is 0.079% of the $2.95 billion portfolio of Passport Capital. Joel Greenblatt owns 69,345 shares as of 03/31/2012, an increase of 110.46% from the previous quarter. This position accounts for 0.14% of the $1.15 billion portfolio of Gotham Capital. Ron Baron owns 1,795,244 shares as of 03/31/2012, which accounts for 0.25% of the $16.69 billion portfolio of Baron Funds. Aside from CEO Kiani, there have been very few other insider buys. However, directors and other insiders have been continually selling the stock since 2009. Director Jack W. Lasersohn bought 1,000 shares of MASI stock on 06/01/2012 at the average price of $18.38. Jack W Lasersohn owns at least 1,000 shares after this. The price of the stock has increased by 0.11% since. Director Robert Coleman sold 62,000 shares of MASI stock on 03/30/2012 at the average price of 23.35. Robert Coleman owns at least 70,200 shares after this. The price of the stock has decreased by 21.2% since. Since Masimo went public in 2007, the company’s revenues have been consistently increasing at an average of 12.01% per year. EPS growth is not as consistent, but is average at 17.42% growth per year. The company holds $130 million in cash as of December 2011, and during the fourth quarter 2011 bought back $30.24 million worth of stock. Previously, the company had been consistently issuing new shares. Masimo has no long-term debt and few liabilities in comparison to its assets.
Sorry, only registered users may post in this forum.
Please Login if you have an account or Create a Free Account if you don't |
RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.



